How long does it take for sparsentan/sparsentan to be available in China?

Sparsentan is a cardiovascular drug commonly used for primary immunoglobulin A (IgA) nephropathy, trade name Filspari. Sparsentan, an endothelin and angiotensin II receptor antagonist, is the only once-daily, oral, non-immunosuppressive drug that directly targets glomerular damage in the kidneys by blocking two key pathways for IgAN disease progression (endothelin-1 and angiotensin II). The most common side effects include limb swelling, hypotension, dizziness, hyperkalemia, anemia, kidney damage, and increased liver enzymes in the blood. It was approved for medical use in the United States in February 2023, and the U.S. Food and Drug Administration (FDA) considered it a first-class drug.

The drug launch process usually involves multiple stages, from research and development to clinical trials, to registration applications and approvals, and this series of processes often takes several years. As a treatment drug for specific diseases, the accumulation and analysis of clinical trial data for sparsentane are the key to ensuring the safety and effectiveness of the drug. These clinical data not only need to be recognized by international regulatory agencies, but also meet the relevant standards of the China Food and Drug Administration. During this process, many factors such as the production process, ingredients, and clinical effects of the drug will be strictly scrutinized.

The Chinese market is paying more and more attention to the introduction of new drugs, especially in the treatment of chronic kidney disease and other related diseases, where patient demand is increasing. Therefore, although sparsentin has been approved and marketed in other countries, its entry into the Chinese market will be affected by many factors such as local regulatory policies, market competition, and cooperation with domestic and foreign pharmaceutical companies. Pharmaceutical companies usually determine drug promotion strategies based on market demand and regulatory environment.